Hope restored: The critical role that Minimal Residual Disease can play in blood cancer patient care

Headshot of Kevin Conroy

Kevin Conroy

Board Member

Kevin Conroy has served on our board of directors since April 2019. Kevin has served as the President, Chief Executive Officer and Chairman of the board of directors of Exact Sciences Corporation, a public molecular diagnostic company, since March 2009. Kevin also serves on the board of directors of Epizyme, Inc., a public clinical-stage biopharmaceutical company, and Arya Sciences Acquisition Corp., a public special purpose acquisition company sponsored by an affiliate of Perceptive Advisors LLC. Prior to joining Exact Sciences Corporation, Kevin served as President and Chief Executive Officer of Third Wave Technologies, Inc., a molecular diagnostics company, from 2005 to 2008. He holds a JD from the University of Michigan Law School and a BS in Electrical Engineering from Michigan State University.